Monday, March 27, 2023
manilastandard.net
ADVERTISEMENT
  • About
  • News
    • Top Stories
    • National
    • World News
    • Pinoy Abroad
    • Features
  • Opinion
    • Editorial
    • Columns
    • Soundbytes
  • LGUs
    • NCR
    • Luzon
    • Visayas
    • Mindanao
  • Business
    • Corporate
    • Economy & Trade
    • Stocks
    • Money
    • Agri & Mining
    • Power & Tech
    • IT & Telecom
  • Sports
    • Basketball
    • Volleyball
    • Fightsports
    • Active
    • Sports Plus
    • One Championship
    • Columns
  • Entertainment
    • TV & Movies
    • Celebrity Profiles
    • Music & Concerts
    • Digital Media
    • Columns
  • Lifestyle
    • Food
    • Culture & Media
    • Fashion
    • Health and Home
    • Leisure
    • Shopping
    • Columns
  • Others
    • Pets
    • Pop.Life
      • Newsmakers
      • Hangouts
      • A-Pop
      • Post Its
      • Performances
      • Malls & Bazaars
      • Hobbies & Collections
    • Technology
      • Gadgets
      • Computers
      • Business
      • Tech Plus
    • MS ON THE ROAD
      • Sedan
      • SUV
      • Truck
      • Bike
      • Accessories
      • Motoring Plus
      • Commuter’s Corner
    • Home & Design
      • Residential
      • Commercial
      • Construction
      • Interior
    • Spotlight
    • Gallery
      • Photos
      • Videos
    • Events
      • Seminars
      • Exhibits
      • Community
    • Biyahero
      • Travel Features
      • Travel Reels
      • Travel Logs
  • Advertise with Us
No Result
View All Result
  • About
  • News
    • Top Stories
    • National
    • World News
    • Pinoy Abroad
    • Features
  • Opinion
    • Editorial
    • Columns
    • Soundbytes
  • LGUs
    • NCR
    • Luzon
    • Visayas
    • Mindanao
  • Business
    • Corporate
    • Economy & Trade
    • Stocks
    • Money
    • Agri & Mining
    • Power & Tech
    • IT & Telecom
  • Sports
    • Basketball
    • Volleyball
    • Fightsports
    • Active
    • Sports Plus
    • One Championship
    • Columns
  • Entertainment
    • TV & Movies
    • Celebrity Profiles
    • Music & Concerts
    • Digital Media
    • Columns
  • Lifestyle
    • Food
    • Culture & Media
    • Fashion
    • Health and Home
    • Leisure
    • Shopping
    • Columns
  • Others
    • Pets
    • Pop.Life
      • Newsmakers
      • Hangouts
      • A-Pop
      • Post Its
      • Performances
      • Malls & Bazaars
      • Hobbies & Collections
    • Technology
      • Gadgets
      • Computers
      • Business
      • Tech Plus
    • MS ON THE ROAD
      • Sedan
      • SUV
      • Truck
      • Bike
      • Accessories
      • Motoring Plus
      • Commuter’s Corner
    • Home & Design
      • Residential
      • Commercial
      • Construction
      • Interior
    • Spotlight
    • Gallery
      • Photos
      • Videos
    • Events
      • Seminars
      • Exhibits
      • Community
    • Biyahero
      • Travel Features
      • Travel Reels
      • Travel Logs
  • Advertise with Us
No Result
View All Result
manilastandard.net
No Result
View All Result
Home Opinion Columns Crossroads by J.A. Dela Cruz

Solidarity trials

J.A. Dela CruzbyJ.A. Dela Cruz
September 17, 2021, 12:20 am
in Crossroads by J.A. Dela Cruz
Reading Time: 4 mins read
A A
Share on FacebookShare on TwitterShare on Email

Solidarity trials"We have reached the end of lockdowns and quarantines as the primary tools in fighting this invisible enemy."

 

 

There is hope, indeed. Scientists and medical experts across the globe are working intensely to discover possible treatment protocols against the ravaging COVID-19 virus as the world enters the second year of its destructive spell. Aside from the six (is it seven now?) vaccines produced at  warp speed,, the effort is to find lasting treatment or at the very least with the potential to reduce the mortality and transmissibility of this virus. The vaccines, after all, were designed primarily to prevent the spread of the virus and, hopefully, inoculate as many of the population to achieve herd immunity.

This is why the World Health Organization (WHO) and a number of other institutions, including governments, have embarked on programs initially repurposing drugs already used for the treatment of other diseases. Or, as Chinese, Israeli and European scientists are now collaborating on, the eventual discovery of new drugs which can also be repurposed for other diseases.  

In the case of the WHO, it has embarked on what it calls a Solidarity PLUS Trial to initially check the potential of three drugs, namely, artesunate, inflixmab and imatinib, chosen by a panel of experts precisely for their potential as COVID-19 treatment. The WHO noted that these drugs were donated by the manufacturers, in this case Ipca, Johnson and Johnson and Novartis, respectively, for the trial with the understanding that these companies will “support access to the drugs at reasonable prices if proven to be effective.”  By participating in this trial, the WHO and the manufacturers hope to shorten the period for certification of these drugs for use by the regulatory agencies such as the US FDA and CDC.  

ADVERTISEMENT

Presently, artesunate is being used to treat malaria and other parasitic diseases and has been in the market for over 30 years. As an anti-malaria treatment, it is being evaluated for its anti-inflammatory properties. It is proposed to be intravenously administered for seven days using the standard dose recommended for the treatment of severe malaria. We note that early on two other anti-malaria drugs, chloroquine and hydroxychloroquine, were also touted as possible COVID-19 treatments. In fact, chloroquine was given a US FDA approval for emergency use (EUA) on March 29, 2020 as COVID-19 was surging for clinical trials. This was, however, withdrawn in June 2020. 

Like its twin, hydroxychloroquine, it remains possible to use this drug under the direction of a doctor under clinical trials as these two drugs can cause heart rhythm problems. After those initial bursts, we have not heard any kind of progress on these trials. Hopefully, artesunate will not suffer the same fate as the earlier drugs.

On the other hand, imatinib, manufactured by giant pharmaceutical company, Novartis, is considered an inhibitor. Formulated as an oral chemotherapy drug used to treat certain types of cancer, the drug is supposed to reverse pulmonary capillary leak. In a randomized clinical trial performed in the Netherlands, it was noted that it might be able to confer clinical benefits to hospitalized COVID-19 patients without comorbidities or other safety issues.  This is also an oral drug and administered once daily for 14 days using the standard maintenance dose except for patients with hematological malignancies, in which case the doses are given over extended periods,  

The third drug under the Solidarity PLUS Trial, infliximab, is a TNF alpha inhibitor which has been approved for treatment of certain autoimmune inflammatory conditions for more than 20 years. This Johnson and Johnson drug has  demonstrated “favorable efficacy and safety in restricting broad spectrum inflammation, including in elderly populations who are most clinically vulnerable to COVID-19.”

Like the WHO trials, Israeli scientists are busy testing three drugs in a Jerusalem laboratory for possible repurposing as anti-COVID 19 treatments. Global news outlets reported that these three existing drugs in question — darapladib, which currently treats atherosclerosis; the cancer drug flumatinib; and an HIV medicine — all have good prospects as such treatments. Chosen for their ability to target two other proteins not traditionally associated with COVID-19’s spike protein, these drugs are likely to remain effective in spite of mutations. By targeting the envelope protein and the 3A protein variants, Professor Isiah Arkin, the Hebrew biochemist behind the research, noted that “these proteins — especially the envelope protein — hardly change between variants, and even between diseases from the coronavirus family.”

In a report in the Israel Times, Arkin, part of a Hebrew University center that specializes in repurposing existing drugs, said that he screened more than 3,000 medicines for suitability, in what he describes as a needle-in-a-haystack search to “provide a fast track to find treatments as the drugs have already been tried and tested for other diseases.” He noted that even if we had the vaccine, we shouldn’t rest on our laurels and these drugs, once proven effective, can “become part of the arsenal that we use to fight the coronavirus.”

The big difference between the Hebrew University research undertaking and that of the WHO Solidarity trials and other research efforts in other countries is that up until now, the envelope protein has not been  seen as a promising target for drugs. But Arkin’s team identified it as an “ion channel, a class of proteins that are located in the membranes of all organisms, which because of their structure respond particularly well to drugs — a quality exploited by pharmaceutical products for high blood pressure, angina and many other conditions,”    thus widening the space for experimentation and discovery.  

Arkin said: “The prospect of helping to widen the arsenal we have against the coronavirus is what needs to be worked on considering the fact that what allows us to fight HIV, hepatitis and many other diseases, is precisely the fact that we have a variety of treatments — a large arsenal.” Indeed, aside from the vaccines and the mandated health protocols, we have to push hard and accelerate the repurposing and discovery of new treatments to save lives and livelihoods. For if truth be said, we have reached the end of lockdowns and quarantines as the primary tools in fighting this invisible enemy.

Tags: COVID-19Solidarity PLUS TrialWorld Health Organization
ADVERTISEMENT
J.A. Dela Cruz

J.A. Dela Cruz

Related Posts

Of course, it was BBM’s project

byJ.A. Dela Cruz
October 20, 2021, 12:30 am
0
794
Of course, it was BBM’s project

"Rappler did not even bother to check."   I am talking about the now-famous Bangui Windmills in Ilocos Norte which...

Read more

PAREX

byJ.A. Dela Cruz
October 11, 2021, 12:05 am
0
13
PAREX

"This project is the product of countless studies."   It is unfortunate that this early, even before the final design...

Read more

Marching on

byJ.A. Dela Cruz
September 27, 2021, 12:15 am
0
8
Marching on

"These Filipinos make us proud."   No, we are not talking here about the raft of declarations of candidacy of...

Read more

‘No one needs to die from COVID-19’

byJ.A. Dela Cruz
September 24, 2021, 12:10 am
0
26
‘No one needs to die from COVID-19’

"No one needs to die from COVID-19" is the ringing message of Dr. George Fareed, a 76-year-old medical practitioner in...

Read more

Binay Part Two?

byJ.A. Dela Cruz
September 15, 2021, 12:00 am
0
17
Binay Part Two?

"The entire operation smelled like the hatchet job the Binay camp decried it to be."   A number of our...

Read more

Battle of the teens

byJ.A. Dela Cruz
September 13, 2021, 12:05 am
0
8
Battle of the teens

"The records made by these teen tennis sensations are for the ages."     In the end, Britain’s Emma Raducano...

Read more

Print Edition

View More

Recent Posts

  • Explosives found at Teves mill
  • First Lady posts snap of Imelda to put rumors of demise to rest
  • Standard debuts ‘Environment & Sustainability’
  • San Miguel cop chief shot dead in robbery try
  • Oil spill compensation seen eclipsing P1.1-b 2006 record
  • Brace for water interruptions, El Niño—Maynilad
  • SC sides with LTO on card project
  • Gov’t letting US dictate terms of EDCA—group

Advertisement

Latest News

Brace for water interruptions, El Niño—Maynilad

byRio N. Araja
March 27, 2023, 1:45 am
0
8
Marinduque lauds desalination project, sees end to potable water supply woes

Water concessionaire Maynilad has advised the public to be ready for possible water interruptions in the coming dry season and...

Read more

SC sides with LTO on card project

byRey E. Requejo
March 27, 2023, 1:35 am
0
8
SC sides with LTO on card project

The Supreme Court has ruled that the Land Transportation Office (LTO)’s use of the P341.7 million left in its 2016...

Read more

Gov’t letting US dictate terms of EDCA—group

byManila Standard
March 27, 2023, 1:30 am
0
8
Southwoods nails Seniors’ Fil golf crown

The Marcos administration has been misleading Filipinos on the Enhanced Defense Cooperation Agreement (EDCA) by letting the United States dictate...

Read more

The capable Lady Legislators of Western and Central Visayas

byPatricia Bianca S. Taculao
March 27, 2023, 1:25 am
0
8
The capable Lady Legislators of Western and Central Visayas

Due to its booming economy, rich history and culture, and captivating landscapes, the island group of Visayas continuously impresses local...

Read more

San Miguel companies post key water savings milestone

byManila Standard
March 27, 2023, 1:20 am
0
8
MPIF Enlarges Blue Footprint for PH Biodiversity Protection & Conservation

San Miguel Corp. recorded a milestone on World Water Day (March 23, 2023) after its businesses collectively saved some 33,865,901,000...

Read more

Advertisement

ADVERTISEMENT
Facebook Twitter Instagram Youtube

ABOUT US

Manila Standard

Manila Standard website (manilastandard.net), launched in August 2002, extends the newspaper’s reach beyond its traditional readers and makes its brand of Philippine news and opinion available to a much wider and geographically diverse readership here and overseas.

Digital Edition

In tone and content, the online edition mirrors the editorial thrust of the newspaper. While hewing to the traditional precepts of fairness and objectivity, MS believes the news of the day need not be staid, overly long or dry. Stories are succinct, readable and written in a lively style that has become a hallmark of the newspaper.

Download – Today’s Paper

Search

No Result
View All Result

6th Floor Universal Re Bldg., 106 Paseo De Roxas cor. Perea Street, Legaspi Village, 1226 Makati City Philippines

Trunklines: 832-5554, 832-5556, 832-5558

© 2021 Manila Standard - Designed and Developed by Neitiviti Studios.

No Result
View All Result
  • About
  • News
    • Top Stories
    • National
    • World News
    • Pinoy Abroad
    • Features
  • Opinion
    • Editorial
    • Columns
    • Soundbytes
  • LGUs
    • NCR
    • Luzon
    • Visayas
    • Mindanao
  • Business
    • Corporate
    • Economy & Trade
    • Stocks
    • Money
    • Agri & Mining
    • Power & Tech
    • IT & Telecom
  • Sports
    • Basketball
    • Volleyball
    • Fightsports
    • Active
    • Sports Plus
    • One Championship
    • Columns
  • Entertainment
    • TV & Movies
    • Celebrity Profiles
    • Music & Concerts
    • Digital Media
    • Columns
  • Lifestyle
    • Food
    • Culture & Media
    • Fashion
    • Health and Home
    • Leisure
    • Shopping
    • Columns
  • Pop.Life
    • Newsmakers
    • Hangouts
    • A-Pop
    • Post Its
    • Performances
    • Malls & Bazaars
    • Hobbies & Collections
  • Technology
    • Gadgets
    • Computers
    • Business
    • Tech Plus
  • MS ON THE ROAD
    • Sedan
    • SUV
    • Truck
    • Bike
    • Accessories
    • Motoring Plus
    • Commuter’s Corner
  • Home & Design
    • Residential
    • Commercial
    • Construction
    • Interior
  • Spotlight
  • Gallery
    • Photos
    • Videos
  • Events
    • Seminars
    • Exhibits
    • Community
  • Biyahero
    • Travel Features
    • Travel Reels
    • Travel Logs
  • Pets
  • Advertise with Us

© 2021 Manila Standard - Designed and Developed by Neitiviti Studios.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Install Manila Standard Web App

Install App